| abstract |
The use of a compound of the general formula ** Formula ** in which R1 / R2 independently of each other are hydrogen, C1-7 alkyl, -CH2) or -cycloalkyl, in which o is the number 0 or 1, or they are benzyl or heterocycloalkyl; or R1 and R2 together with the N atom to which they are attached form a ring containing - (CH2) 3-, - (CH2) 4-, - (CH2) 5-, - (CH2) 2-O- (CH2 ) 2-, - (CH2) 2-S- (CH2) 2 -, - (CH2) 2-NR- (CH2) 2-, - (CH2) 2-C (O) - (CH2) 2-, - (CH2) 2-CF2- (CH2) 2-, -CH2- CHR- (CH2) 2, -CHR- (CH2) 3, CHR- (CH2) 2-CHR-, or is the 2,6-diaza ring -tert-butyl spiro [3.3] heptane-2-carboxylate and R is hydroxy, halogen, cycloalkyl or C (O) O-C1-7 alkyl ,; X is - (CH2) 4-, - (CH2) 3-, - (CH2) 2- or -CH2-; R3 is S-C1-C7 alkyl, CF3, OCHF2, C1-7 alkoxy, C1-7 alkyl, phenyl, cycloalkyl or halogen; R4 is CF3, C1-7 alkoxy, C1-7 alkyl or halogen and n is number 1 or 2; or a pharmaceutically acceptable acid addition salt, a racemic mixture, or their corresponding enantiomers and / or the optical isomers thereof for the manufacture of a medicament intended for the treatment of psychosis, memory and learning dysfunction, attention deficit, schizophrenia, dementia disorders or Alzheimer's disease. |